Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Retained Earnings (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Retained Earnings for 16 consecutive years, with -$254.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 471475.93% to -$254.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$254.5 million, a 471475.93% decrease, with the full-year FY2024 number at -$259.5 million, down 6.77% from a year prior.
  • Retained Earnings was -$254.5 million for Q3 2025 at Xtant Medical Holdings, down from $152000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $152000.0 in Q2 2025 to a low of -$259.5 million in Q4 2024.
  • A 5-year average of -$204.2 million and a median of -$239.1 million in 2022 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 100.06% in 2025; the steepest drop was 471475.93% in 2025.
  • Xtant Medical Holdings' Retained Earnings stood at -$235.2 million in 2021, then fell by 3.61% to -$243.7 million in 2022, then grew by 0.27% to -$243.0 million in 2023, then decreased by 6.77% to -$259.5 million in 2024, then rose by 1.89% to -$254.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Retained Earnings are -$254.5 million (Q3 2025), $152000.0 (Q2 2025), and -$209000.0 (Q1 2025).